ScholarIQanswers from OpenAlex & ORCID
Valter Torri
ResearcherPublications, citations & collaboration network
Valter Torri is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Valter Torri have?
ScholarIQindexed works
Valter Torri has 656 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Valter Torri have?
ScholarIQcitation count
Valter Torri has 41,272 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Valter Torri?
ScholarIQh-index
Valter Torri has an h-index of 89 in OpenAlex.
What is the i10-index of Valter Torri?
ScholarIQi10-index
Valter Torri has an i10-index of 290 in OpenAlex.
What is the ORCID of Valter Torri?
ScholarIQorcid
The ORCID for Valter Torri is on the source record.
What is the OpenAlex record for Valter Torri?
ScholarIQopenalex
The OpenAlex for Valter Torri is on the source record.
What are the most-cited papers on Valter Torri?
ScholarIQmost cited works
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
Jean‐Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti, Jean-Yves Douillard, Frances A. Shepherd, Richard Stephens, Ariane Dunant, Valter Torri, Rafael Rosell, Lesley Seymour, Stephen Spiro, Estelle Rolland, Roldano Fossati, D. Aubert, Keyue Ding, David Waller, Thierry Le Chevalier
Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial
Pierluigi Benedetti Panici, S. Basile, F. Maneschi, Andrea Alberto Lissoni, Mauro Signorelli, Giovanni Scambia, Roberto Angioli, Saverio Tateo, Giorgia Mangili, Dionyssios Katsaros, G Garozzo, E Campagnutta, Nicoletta Donadello, Stefano Greggi, Mauro Melpignano, Francesco Raspagliesi, Nicola Ragni, Gennaro Cormio, Roberto Grassi, Massimo Piergiuseppe Franchi, Diana Giannarelli, Roldano Fossati, Valter Torri, M. Amoroso, C. Della Croce, Costantino Mangioni
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
Mahesh Parmar, Jonathan A. Ledermann, Nicoletta Colombo, Andreas du Bois, Delaloye Jf, Gunnar B. Kristensen, Sarah Wheeler, Ann Marie Swart, W. Qian, Valter Torri, Irene Floriani, Gordon C. Jayson, Alan Lamont, C. Tropé
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto Sobrero, Anthony F. Shields, Takayuki Yoshino, James Paul, Julien Taı̈eb, John Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca, Jeffrey A. Meyerhardt, Déwi Vernerey, Takeharu Yamanaka, Ioannis Boukovinas, Jeffrey P. Meyers, Lindsay A. Renfro, Donna Niedzwiecki, Toshiaki Watanabe, Valter Torri, Mark Saunders, Daniel J. Sargent, Thierry André, Timothy Iveson
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Francesco Leone, Ilaria Depetris, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello, Patrizia Racca, Andrea Bertotti, Giulia Siravegna, Valter Torri, Alessio Amatu, Silvia Ghezzi, Giovanna Marrapese, Laura Palmeri, Emanuele Valtorta, Andrea Cassingena, Calogero Lauricella, Angelo Vanzulli, Daniele Regge, Silvio Veronese, Paolo M. Comoglio, Alberto Bardelli, Silvia Marsoni, Salvatore Siena